11 December 2018 | NewsVaccine safety in Australia AusVaxSafety summary report 2016-17Read the full article
The first NCIRS seminar covers the internationally controversial area of pneumococcal vaccines for elderly adults. Persons over 65 have a progressively increasing incidence of pneumococcal invasive disease and pneumonia but both available vaccines have limitations. In Australia the PBAC has recommended, in principle, moving from 23 valent polysaccharide vaccine to 13 valent conjugate vaccine to prevent pneumonia.
Epidemiologists Prof. Robert Booy and Dr Sanjay Jayasinghe presented on the issues on Wednesday 22nd February 2017.
Introduction by Prof. P. McIntyre and Talk 1: Pneumococcal disease epidemiology in the elderly & 13vPCV efficacy by Sanjay Jayasinghe
Talk 2: Comparing the effectiveness of polysaccharide pneumococcal vaccine in bacteremic and non-bacteremic pneumonia: Focus on pneumococcal pneumonia by Prof. Robert Booy
Questions & Discussion: Pneumococcal Vaccines for Elderly Adults
Dr Sanjay Jayasinghe is Research Fellow at NCIRS and a member of the team that provides evidence-based support for immunisation policy development. HIs work involves assessment of the effectiveness of pneumococcal vaccinations in Australian children and the role of perinatal risk factors in the development of invasive pneumococcal disease.
Professor Robert Booy is the Head of Clinical Research at NCIRS. His research interests extend from understanding the genetic basis of susceptibility to, and severity of, infectious diseases, especially influenza and invasive disease caused by encapsulated organisms; the clinical, public health, social and economic burden of these diseases; and means by which to prevent or control serious infections through vaccines, drugs and non-pharmaceutical measures.
NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 | Fax (612) 9845 1418 | ABN 53 188 579 090
We acknowledge that the National Centre for Immunisation Research & Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.
Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.